Characterization of metabolic differences between benign and malignant tumors: High-spectral-resolution diffuse optical spectroscopy

Radiology

Volumn 254, Issue 1, 2010, Pages 277-284

  Kukreti, Shwayta ^a,b,c,d   Cerussi, Albert E ^a,b   Tanamai, Wendy ^a   Hsiang, David ^f   Tromberg, Bruce J ^a,b,e   Gratton, Enrico ^a,b,d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^e University of California at Irvine   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABSORPTION SPECTROSCOPY; ADULT; AGED; ARTICLE; BENIGN TUMOR; BREAST CANCER; BREAST FIBROADENOMA; BREAST TUMOR; COMPUTER PROGRAM; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSE OPTICAL SPECTROSCOPY; FEMALE; HUMAN; INFRARED SPECTROSCOPY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; SPECTROMETER; TUMOR DIAGNOSIS; ALGORITHM; CASE CONTROL STUDY; DISCRIMINANT ANALYSIS; INSTRUMENTATION; LABORATORY DIAGNOSIS; METABOLISM; MIDDLE AGED; NEAR INFRARED SPECTROSCOPY; NONPARAMETRIC TEST; PATHOLOGY; PREDICTION AND FORECASTING; SENSITIVITY AND SPECIFICITY;

TUMOR MARKER;

ADULT; AGED; ALGORITHMS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DISCRIMINANT ANALYSIS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SPECTROSCOPY, NEAR-INFRARED; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 75349088884     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.09082134     Document Type: Article

References (35)

1. Gribbestad IS, Sitter B, Lundgren S, Krane J, Axelson D. Metabolite composition in breast tumors examined by proton nuclear magnetic resonance spectroscopy. Anticancer Res 1999;19:1737-1746.
2. Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE. Human breast lesions: characterization with proton MR spectroscopy. Radiology 1998;209:269-275.
3. Kvistad KA, Bakken IJ, Gribbestad IS, et al. Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging 1999;10:159-164.
4. Jagannathan NR, Kumar M, Seenu V, et al. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 2001;84:1016-1022.
5. Yeung DK, Chan Y, Leung S, Poon PM, Pang C. Detection of an intense resonance at 2.4 ppm in 1H MR spectra of patients with severe late-delayed, radiation-induced brain injuries. Magn Reson Med 2001;45:994-1000.
6. Cecil KM, Schnall MD, Siegelman ES, Lenkinski RE. The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy. Breast Cancer Res Treat 2001;68:45-54.
7. Tse GM, Yeung DK, King AD, Cheung HS, Yang WT. In vivo proton magnetic resonance spectroscopy of breast lesions: an update. Breast Cancer Res Treat 2007;104:249-255.
8. Bolan PJ, Meisamy S, Baker EH, et al. In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn Reson Med 2003;50:1134-1143.
9. Kim JK, Park SH, Lee HM, et al. In vivo 1H-MRS evaluation of malignant and benign breast diseases. Breast 2003;12:179-182.
10. Meisamy S, Bolan PJ, Baker EH, et al. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy - a pilot study at 4 T. Radiology 2004;233:424-431.
11. Kumar M, Jagannathan NR, Seenu V, Dwivedi SN, Julka PK, Rath GK. Monitoring the therapeutic response of locally advanced breast cancer patients: sequential in vivo proton MR spectroscopy study. J Magn Reson Imaging 2006;24:325-332.
12. Manton DJ, Chaturvedi A, Hubbard A, et al. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 2006;94:427-435.
13. Pogue BW, Poplack SP, McBride TO, et al. Quantitative hemoglobin tomography with diffuse near-infrared spectroscopy: pilot results in the breast. Radiology 2001;218:261-266.
14. Taroni P, Danesini G, Torricelli A, Pifferi A, Spinelli L, Cubeddu R. Clinical trial of time-resolved scanning optical mammography at 4 wavelengths between 683 and 975 nm. J Biomed Opt 2004;9:464-473.
15. Chance B, Nioka S, Zhang J, et al. Breast cancer detection based on incremental biochemical and physiological properties of breast cancers: a six-year, two-site study. Acad Radiol 2005;12:925-933.
16. Zhu Q, Cronin EB, Currier AA, et al. Benign versus malignant breast masses: optical differentiation with US-guided optical imaging reconstruction. Radiology 2005;237:57-66.
17. Grosenick D, Wabnitz H, Moesta KT, Mucke J, Schlag PM, Rinneberg H. Time-domain scanning optical mammography. II. Optical properties and tissue parameters of 87 carcinomas. Phys Med Biol 2005;50:2451-2468.
18. Xu RX, Povoski SP. Diffuse optical imaging and spectroscopy for cancer. Expert Rev Med Devices 2007;4:83-95.
19. Choe R, Corlu A, Lee K, et al. Diffuse optical tomography of breast cancer during neoadjuvant chemotherapy: a case study with comparison to MRI. Med Phys 2005;32:1128-1139.
20. Zhu Q, Kurtzma SH, Hegde P, et al. Utilizing optical tomography with ultrasound localization to image heterogeneous hemo globin distribution in large breast cancers. Neoplasia 2005;7:263-270.
21. Cerussi AE, Jakubowski D, Shah N, et al. Spectroscopy enhances the information content of optical mammography. J Biomed Opt 2002;7:60-71.
22. Cerussi A, Hsiang D, Shah N, et al. Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy. Proc Natl Acad Sci U S A 2007;104:4014-4019.
23. Shah N, Gibbs J, Wolverton D, Cerussi A, Hylton N, Tromberg BJ. Combined diffuse optical spectroscopy and contrast-enhanced magnetic resonance imaging for monitoring breast cancer neoadjuvant chemotherapy: a case study. J Biomed Opt 2005;10:051503.
24. Cerussi A, Shah N, Hsiang D, Durkin A, Butler J, Tromberg BJ. In vivo absorption, scattering, and physiologic properties of 58 malignant breast tumors determined by broadband diffuse optical spectroscopy. J Biomed Opt 2006;11:044005.
25. Intes X. Time-domain optical mammography SoftScan: initial results. Acad Radiol 2005;12:934-947.
26. Pogue BW, Jiang S, Dehghani H, et al. Characterization of hemoglobin, water, and NIR scattering in breast tissue: analysis of intersubject variability and menstrual cycle changes. J Biomed Opt 2004;9:541-552.
27. Cubeddu R, D'Andrea C, Pifferi A, Taroni P, Torricelli A, Valentini G. Effects of the menstrual cycle on the red and near-infrared optical properties of the human breast. Photochem Photobiol 2000;72:383-391.
28. Kukreti S, Cerussi A, Tromberg B, Gratton E. Intrinsic tumor biomarkers revealed by novel double-differential spectroscopic analysis of near-infrared spectra. J Biomed Opt 2007;12:020509.
29. Pham TH, Coquoz O, Fishkin JB, Anderson E, Tromberg BJ. Broad bandwidth frequency domain instrument for quantitative tissue optical spectroscopy. Rev Sci Instrum 2000;71:2500-2513.
30. Bevilacqua F, Berger AJ, Cerussi AE, Jakubowski D, Tromberg BJ. Broadband absorption spectroscopy in turbid media by combined frequency-domain and steady-state methods. Appl Opt 2000;39:6498-6507.
31. Jakubowski DB, Cerussi AE, Bevilacqua F, et al. Monitoring neoadjuvant chemotherapy in breast cancer using quantitative diffuse optical spectroscopy: a case study. J Biomed Opt 2004;9:230-238.
32. Franceschini MA, Moesta KT, Fantini S, et al. Frequency-domain techniques enhance optical mammography: initial clinical results. Proc Natl Acad Sci U S A 1997;94:6468-6473.
33. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst 2002;94:1197-1203.
34. Kleinfeld AM, Okada C. Free fatty acid release from human breast cancer tissue inhibits cytotoxic T-lymphocyte-mediated killing. J Lipid Res 2005;46:1983-1990.
35. Chow LW, Cheng CW, Wong JL, Toi M. Serum lipid profiles in patients receiving endocrine treatment for breast cancer: the results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial. Biomed Pharmacother 2005;59(suppl 2):S302-S305.